The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Parkinson’s Disease Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Parkinson's disease therapeutics includes medications and therapies used to manage the symptoms of Parkinson's disease, a neurodegenerative disorder that affects movement and motor control.
The global Parkinson’s Disease Therapeutics market size is expected to reach US$ 3533.7 million by 2029, growing at a CAGR of 6.0% from 2023 to 2029. The market is mainly driven by the significant applications of Parkinson’s Disease Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Parkinson’s Disease Therapeutics market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Transdermal segment is estimated at % CAGR for the next seven-year period.
The market for Parkinson's disease therapeutics is driven by the increasing prevalence of Parkinson's disease and the demand for symptomatic relief and disease-modifying treatments. The market's growth is also influenced by ongoing research in Parkinson's disease pathophysiology and the development of novel therapeutic approaches.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Parkinson’s Disease Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Parkinson’s Disease Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Parkinson’s Disease Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Parkinson’s Disease Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Parkinson’s Disease Therapeutics covered in this report include Abbvie, Biogen, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline, H. Lundbeck A/S, Impax Labs, Newron Pharmaceuticals SpA and Novartis AG, etc.
The global Parkinson’s Disease Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbvie
Biogen
Boehringer Ingelheim GmbH
F. Hoffman-La Roche
GlaxoSmithKline
H. Lundbeck A/S
Impax Labs
Newron Pharmaceuticals SpA
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Global Parkinson’s Disease Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Parkinson’s Disease Therapeutics market, Segment by Type:
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Global Parkinson’s Disease Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Parkinson’s Disease Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Parkinson's disease therapeutics includes medications and therapies used to manage the symptoms of Parkinson's disease, a neurodegenerative disorder that affects movement and motor control.
The global Parkinson’s Disease Therapeutics market size is expected to reach US$ 3533.7 million by 2029, growing at a CAGR of 6.0% from 2023 to 2029. The market is mainly driven by the significant applications of Parkinson’s Disease Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Parkinson’s Disease Therapeutics market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Transdermal segment is estimated at % CAGR for the next seven-year period.
The market for Parkinson's disease therapeutics is driven by the increasing prevalence of Parkinson's disease and the demand for symptomatic relief and disease-modifying treatments. The market's growth is also influenced by ongoing research in Parkinson's disease pathophysiology and the development of novel therapeutic approaches.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Parkinson’s Disease Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Parkinson’s Disease Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Parkinson’s Disease Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Parkinson’s Disease Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Parkinson’s Disease Therapeutics covered in this report include Abbvie, Biogen, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline, H. Lundbeck A/S, Impax Labs, Newron Pharmaceuticals SpA and Novartis AG, etc.
The global Parkinson’s Disease Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbvie
Biogen
Boehringer Ingelheim GmbH
F. Hoffman-La Roche
GlaxoSmithKline
H. Lundbeck A/S
Impax Labs
Newron Pharmaceuticals SpA
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Global Parkinson’s Disease Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Parkinson’s Disease Therapeutics market, Segment by Type:
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Global Parkinson’s Disease Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Parkinson’s Disease Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Parkinson’s Disease Therapeutics
1.1 Parkinson’s Disease Therapeutics Market Overview
1.1.1 Parkinson’s Disease Therapeutics Product Scope
1.1.2 Parkinson’s Disease Therapeutics Market Status and Outlook
1.2 Global Parkinson’s Disease Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Parkinson’s Disease Therapeutics Market Size by Region (2018-2029)
1.4 Global Parkinson’s Disease Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Parkinson’s Disease Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Parkinson’s Disease Therapeutics Market Size (2018-2029)
1.6.1 North America Parkinson’s Disease Therapeutics Market Size (2018-2029)
1.6.2 Europe Parkinson’s Disease Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Parkinson’s Disease Therapeutics Market Size (2018-2029)
1.6.4 Latin America Parkinson’s Disease Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Parkinson’s Disease Therapeutics Market Size (2018-2029)
2 Parkinson’s Disease Therapeutics Market by Type
2.1 Introduction
2.1.1 Oral
2.1.2 Transdermal
2.1.3 Subcutaneous
2.1.4 Intestinal Infusion
2.2 Global Parkinson’s Disease Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Parkinson’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Parkinson’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Parkinson’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Parkinson’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Parkinson’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
3 Parkinson’s Disease Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Parkinson’s Disease Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Parkinson’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Parkinson’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Parkinson’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Parkinson’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Parkinson’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
4 Parkinson’s Disease Therapeutics Competition Analysis by Players
4.1 Global Parkinson’s Disease Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Parkinson’s Disease Therapeutics as of 2022)
4.3 Date of Key Players Enter into Parkinson’s Disease Therapeutics Market
4.4 Global Top Players Parkinson’s Disease Therapeutics Headquarters and Area Served
4.5 Key Players Parkinson’s Disease Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Parkinson’s Disease Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbvie
5.1.1 Abbvie Profile
5.1.2 Abbvie Main Business
5.1.3 Abbvie Parkinson’s Disease Therapeutics Products, Services and Solutions
5.1.4 Abbvie Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Abbvie Recent Developments
5.2 Biogen
5.2.1 Biogen Profile
5.2.2 Biogen Main Business
5.2.3 Biogen Parkinson’s Disease Therapeutics Products, Services and Solutions
5.2.4 Biogen Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Biogen Recent Developments
5.3 Boehringer Ingelheim GmbH
5.3.1 Boehringer Ingelheim GmbH Profile
5.3.2 Boehringer Ingelheim GmbH Main Business
5.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Products, Services and Solutions
5.3.4 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 F. Hoffman-La Roche Recent Developments
5.4 F. Hoffman-La Roche
5.4.1 F. Hoffman-La Roche Profile
5.4.2 F. Hoffman-La Roche Main Business
5.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Products, Services and Solutions
5.4.4 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 F. Hoffman-La Roche Recent Developments
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business
5.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Products, Services and Solutions
5.5.4 GlaxoSmithKline Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 GlaxoSmithKline Recent Developments
5.6 H. Lundbeck A/S
5.6.1 H. Lundbeck A/S Profile
5.6.2 H. Lundbeck A/S Main Business
5.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Products, Services and Solutions
5.6.4 H. Lundbeck A/S Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 H. Lundbeck A/S Recent Developments
5.7 Impax Labs
5.7.1 Impax Labs Profile
5.7.2 Impax Labs Main Business
5.7.3 Impax Labs Parkinson’s Disease Therapeutics Products, Services and Solutions
5.7.4 Impax Labs Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Impax Labs Recent Developments
5.8 Newron Pharmaceuticals SpA
5.8.1 Newron Pharmaceuticals SpA Profile
5.8.2 Newron Pharmaceuticals SpA Main Business
5.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Products, Services and Solutions
5.8.4 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Newron Pharmaceuticals SpA Recent Developments
5.9 Novartis AG
5.9.1 Novartis AG Profile
5.9.2 Novartis AG Main Business
5.9.3 Novartis AG Parkinson’s Disease Therapeutics Products, Services and Solutions
5.9.4 Novartis AG Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Novartis AG Recent Developments
5.10 Orion Corporation
5.10.1 Orion Corporation Profile
5.10.2 Orion Corporation Main Business
5.10.3 Orion Corporation Parkinson’s Disease Therapeutics Products, Services and Solutions
5.10.4 Orion Corporation Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Orion Corporation Recent Developments
5.11 Teva Pharmaceutical Industries Ltd.
5.11.1 Teva Pharmaceutical Industries Ltd. Profile
5.11.2 Teva Pharmaceutical Industries Ltd. Main Business
5.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Products, Services and Solutions
5.11.4 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5.12 UCB S.A.
5.12.1 UCB S.A. Profile
5.12.2 UCB S.A. Main Business
5.12.3 UCB S.A. Parkinson’s Disease Therapeutics Products, Services and Solutions
5.12.4 UCB S.A. Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 UCB S.A. Recent Developments
5.13 Livzon Pharmaceutical
5.13.1 Livzon Pharmaceutical Profile
5.13.2 Livzon Pharmaceutical Main Business
5.13.3 Livzon Pharmaceutical Parkinson’s Disease Therapeutics Products, Services and Solutions
5.13.4 Livzon Pharmaceutical Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Livzon Pharmaceutical Recent Developments
5.14 Haisco Pharmaceutical
5.14.1 Haisco Pharmaceutical Profile
5.14.2 Haisco Pharmaceutical Main Business
5.14.3 Haisco Pharmaceutical Parkinson’s Disease Therapeutics Products, Services and Solutions
5.14.4 Haisco Pharmaceutical Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Haisco Pharmaceutical Recent Developments
5.15 Jingxin Pharmaceutical
5.15.1 Jingxin Pharmaceutical Profile
5.15.2 Jingxin Pharmaceutical Main Business
5.15.3 Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Products, Services and Solutions
5.15.4 Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Jingxin Pharmaceutical Recent Developments
5.16 Dongcheng Biochemicals
5.16.1 Dongcheng Biochemicals Profile
5.16.2 Dongcheng Biochemicals Main Business
5.16.3 Dongcheng Biochemicals Parkinson’s Disease Therapeutics Products, Services and Solutions
5.16.4 Dongcheng Biochemicals Parkinson’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 Dongcheng Biochemicals Recent Developments
6 North America
6.1 North America Parkinson’s Disease Therapeutics Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Parkinson’s Disease Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Parkinson’s Disease Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Parkinson’s Disease Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Parkinson’s Disease Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Parkinson’s Disease Therapeutics Market Dynamics
11.1 Parkinson’s Disease Therapeutics Industry Trends
11.2 Parkinson’s Disease Therapeutics Market Drivers
11.3 Parkinson’s Disease Therapeutics Market Challenges
11.4 Parkinson’s Disease Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
